BibTex RIS Cite

Alerjik rinitli hastalarda serum ve nazal eozinofilik katyonik proteinin immünoterapi etkinliğinin değerlendirilmesindeki rolü

Year 2006, Volume: 16 Issue: 4, 155 - 159, 27.08.2006

Abstract

Amaç: Ev tozu akarlarına duyarlı olan alerjik rinithastalarında spesifik immünoterapinin SİT klinik etkinliğinin bir göstergesi olarak eozinofilik katyonikproteinin EKP rolü ve değeri araştırıldı.Hastalar ve Yöntemler: Çalışmaya sürekli alerjik riniti olan 49 hasta alındı. Hasta grubuna gerekli spesifikimmünoterapi uygulandı. Spesifik immünoterapi öncesinde, altıncı ayda ve tedavi bitiminden iki yıl sonra ölçülen nazal sekresyon ve serumdaki EKP seviyeleri hasta grubu içinde ve sağlıklı bireylerden oluşan 16 kişilik kontrol grubuyla karşılaştırıldı.Bulgular: Hasta grubunda SİT öncesi nazal EKP seviyeleri tedavi sonrası seviyelere oranla anlamlı derecede yüksek bulundu p

References

  • Elberling J, Linneberg A, Dirksen A, Johansen JD, Frolund L, Madsen F, et al. Mucosal symptoms elicited by fragrance products in a population-based sample in relation to atopy and bronchial hyper-reactivity. Clin Exp Allergy 2005;35:75-81.
  • Lee CH, Chuang HY, Shih CC, Jee SH, Wang LF, Chiu HC, et al. Correlation of serum total IgE, eosinophil granule cationic proteins, sensitized allergens and family aggregation in atopic dermatitis patients with or without rhinitis. J Dermatol 2004;31:784-93.
  • Woerly G, Loiseau S, Loyens M, Schoch C, Capron M. Inhibitory effects of ketotifen on eotaxin-dependent activation of eosinophils: consequences for allergic eye diseases. Allergy 2003;58:397-406.
  • Czech W, Krutmann J, Schopf E, Kapp A. Serum eosinophil cationic protein (ECP) is a sensitive mea- sure for disease activity in atopic dermatitis. Br J Dermatol 1992;126:351-5.
  • Ferguson AC, Vaughan R, Brown H, Curtis C. Evaluation of serum eosinophilic cationic protein as a marker of disease activity in chronic asthma. J Allergy Clin Immunol 1995;95(1 Pt 1):23-8.
  • Venge P. Monitoring the allergic inflammation. Allergy 2004;59:26-32.
  • Bez C, Schubert R, Kopp M, Ersfeld Y, Rosewich M, Kuehr J, et al. Effect of anti-immunoglobulin E on nasal inflammation in patients with seasonal allergic rhinoconjunctivitis. Clin Exp Allergy 2004;34:1079-85.
  • Tutluoğlu B, Gemicioğlu B, Yılmaz N, Küçükusta AR, Kılınç Yılmaz G, Yaman M. Hafif astim ve rinitli olgu- larda nazal lavaj sivisi eozinofilik katyonik protein ve triptaz değerlerine heparin ve izotonik sodyum klorürün etkisi. Solunum Dergisi 2000;2:36-41.
  • Juhlin L, Venge P. Eosinophilic cationic protein (ECP) in skin disorders. Acta Derm Venereol 1991;71:495-501.
  • Frigas E, Gleich GJ. The eosinophil and the patho- physiology of asthma. J Allergy Clin Immunol 1986; 77:527-37.
  • Marcucci F, Sensi LG, Migali E, Coniglio G. Eosinophil cationic protein and specific IgE in serum and nasal mucosa of patients with grass-pollen-allergic rhinitis and asthma. Allergy 2001;56:231-6.
  • Andersson M, Andersson P, Venge P, Pipkorn U. Eosinophils and eosinophil cationic protein in nasal lavages in allergen-induced hyperresponsiveness: effects of topical glucocorticosteroid treatment. Allergy 1989;44:342-8.
  • Linder A, Venge P, Deuschl H. Eosinophil cationic pro- tein and myeloperoxidase in nasal secretion as mark- ers of inflammation in allergic rhinitis. Allergy 1987; 42:583-90.
  • Bisgaard H, Gronborg H, Mygind N, Dahl R, Lindqvist N, Venge P. Allergen-induced increase of eosinophil cationic protein in nasal lavage fluid: effect of the glu- cocorticoid budesonide. J Allergy Clin Immunol 1990; 85:891-5.
  • Bascom R, Pipkorn U, Proud D, Dunnette S, Gleich GJ, Lichtenstein LM, et al. Major basic protein and eosinophil-derived neurotoxin concentrations in nasal-lavage fluid after antigen challenge: effect of sys- temic corticosteroids and relationship to eosinophil influx. J Allergy Clin Immunol 1989;84:338-46.
  • Rasp G, Thomas PA, Bujia J. Eosinophil inflammation of the nasal mucosa in allergic and non-allergic rhini- tis measured by eosinophil cationic protein levels in native nasal fluid and serum. Clin Exp Allergy 1994; 24:1151-6.
  • Klimek L, Riechelmann H, Amedee R. Eosinophil cationic protein in nasal secre-tions and blood serum in grass-pollen allergic rhinitis. Am J Rhinol 1996;10:319-23.
  • Walker SM, Varney VA, Gaga M, Jacobson MR, Durham SR. Grass pollen immunotherapy: efficacy and safety during a 4-year follow-up study. Allergy 1995;50:405-13.
  • Pichler CE, Helbling A, Pichler WJ. Three years of spe- cific immunotherapy with house-dust-mite extracts in patients with rhinitis and asthma: significant improve- ment of allergen-specific parameters and of nonspecif- ic bronchial hyperreactivity. Allergy 2001;56:301-6.
  • Durham SR. New insights into the mechanisms of immunotherapy. Eur Arch Otorhinolaryngol 1995;252 Suppl 1:S64-7.
  • Klimek L, Wolf H, Mewes T, Dormann D, Reske-Kunz A, Schnitker J, et al. The effect of short-term immunotherapy with molecular standardized grass and rye allergens on eosinophil cationic protein and tryptase in nasal secretions. J Allergy Clin Immunol 1999;103(1 Pt 1):47-53.
  • Ohashi Y, Nakai Y, Kakinoki Y, Ohno Y, Sakamoto H, Kato A, et al. Effect of immunotherapy on serum lev- els of eosinophil cationic protein in perennial allergic rhinitis. Ann Otol Rhinol Laryngol 1997;106(10 Pt 1):848-53.

The use of serum and nasal eosinophilic cationic protein in the evaluation of the effectiveness of immunotherapy in patients with allergic rhinitis

Year 2006, Volume: 16 Issue: 4, 155 - 159, 27.08.2006

Abstract

Objectives: We investigated the use of eosinophilic cationic protein ECP as an indicator of clinical effi- ciency of specific immunotherapy SIT in patients with allergic rhinitis sensitive to house dust mites.Patients and Methods: Specific immunotherapy was administered to 49 patients 20 males, 29 females; mean age 34.2 years; range 16 to 66 years with perennial allergic rhinitis. Nasal secretion and serum ECP levels were measured before, at the 6th month of, and two years after completion of, treatment.Comparisons were made within the patient group and with a control group of 16 healthy subjects 10 males, 6 females; mean age 23 years; range 17 to 26 years .Results: Pretreatment nasal ECP levels were sig- nificantly higher than those found after the treatment p<0.001 . Nasal ECP levels measured before SIT were significantly different from those of the control group p<0.05 . However, serum ECP levels did not differ significantly between the two groups p>0.05 .Serum ECP levels in the patient group tended to decrease with treatment p>0.05 .Conclusion: We conclude that, in addition to the symptoms and clinical findings, nasal ECP mea- surement may be a reliable and suitable laboratory method to monitor and evaluate the effectiveness of treatment.

References

  • Elberling J, Linneberg A, Dirksen A, Johansen JD, Frolund L, Madsen F, et al. Mucosal symptoms elicited by fragrance products in a population-based sample in relation to atopy and bronchial hyper-reactivity. Clin Exp Allergy 2005;35:75-81.
  • Lee CH, Chuang HY, Shih CC, Jee SH, Wang LF, Chiu HC, et al. Correlation of serum total IgE, eosinophil granule cationic proteins, sensitized allergens and family aggregation in atopic dermatitis patients with or without rhinitis. J Dermatol 2004;31:784-93.
  • Woerly G, Loiseau S, Loyens M, Schoch C, Capron M. Inhibitory effects of ketotifen on eotaxin-dependent activation of eosinophils: consequences for allergic eye diseases. Allergy 2003;58:397-406.
  • Czech W, Krutmann J, Schopf E, Kapp A. Serum eosinophil cationic protein (ECP) is a sensitive mea- sure for disease activity in atopic dermatitis. Br J Dermatol 1992;126:351-5.
  • Ferguson AC, Vaughan R, Brown H, Curtis C. Evaluation of serum eosinophilic cationic protein as a marker of disease activity in chronic asthma. J Allergy Clin Immunol 1995;95(1 Pt 1):23-8.
  • Venge P. Monitoring the allergic inflammation. Allergy 2004;59:26-32.
  • Bez C, Schubert R, Kopp M, Ersfeld Y, Rosewich M, Kuehr J, et al. Effect of anti-immunoglobulin E on nasal inflammation in patients with seasonal allergic rhinoconjunctivitis. Clin Exp Allergy 2004;34:1079-85.
  • Tutluoğlu B, Gemicioğlu B, Yılmaz N, Küçükusta AR, Kılınç Yılmaz G, Yaman M. Hafif astim ve rinitli olgu- larda nazal lavaj sivisi eozinofilik katyonik protein ve triptaz değerlerine heparin ve izotonik sodyum klorürün etkisi. Solunum Dergisi 2000;2:36-41.
  • Juhlin L, Venge P. Eosinophilic cationic protein (ECP) in skin disorders. Acta Derm Venereol 1991;71:495-501.
  • Frigas E, Gleich GJ. The eosinophil and the patho- physiology of asthma. J Allergy Clin Immunol 1986; 77:527-37.
  • Marcucci F, Sensi LG, Migali E, Coniglio G. Eosinophil cationic protein and specific IgE in serum and nasal mucosa of patients with grass-pollen-allergic rhinitis and asthma. Allergy 2001;56:231-6.
  • Andersson M, Andersson P, Venge P, Pipkorn U. Eosinophils and eosinophil cationic protein in nasal lavages in allergen-induced hyperresponsiveness: effects of topical glucocorticosteroid treatment. Allergy 1989;44:342-8.
  • Linder A, Venge P, Deuschl H. Eosinophil cationic pro- tein and myeloperoxidase in nasal secretion as mark- ers of inflammation in allergic rhinitis. Allergy 1987; 42:583-90.
  • Bisgaard H, Gronborg H, Mygind N, Dahl R, Lindqvist N, Venge P. Allergen-induced increase of eosinophil cationic protein in nasal lavage fluid: effect of the glu- cocorticoid budesonide. J Allergy Clin Immunol 1990; 85:891-5.
  • Bascom R, Pipkorn U, Proud D, Dunnette S, Gleich GJ, Lichtenstein LM, et al. Major basic protein and eosinophil-derived neurotoxin concentrations in nasal-lavage fluid after antigen challenge: effect of sys- temic corticosteroids and relationship to eosinophil influx. J Allergy Clin Immunol 1989;84:338-46.
  • Rasp G, Thomas PA, Bujia J. Eosinophil inflammation of the nasal mucosa in allergic and non-allergic rhini- tis measured by eosinophil cationic protein levels in native nasal fluid and serum. Clin Exp Allergy 1994; 24:1151-6.
  • Klimek L, Riechelmann H, Amedee R. Eosinophil cationic protein in nasal secre-tions and blood serum in grass-pollen allergic rhinitis. Am J Rhinol 1996;10:319-23.
  • Walker SM, Varney VA, Gaga M, Jacobson MR, Durham SR. Grass pollen immunotherapy: efficacy and safety during a 4-year follow-up study. Allergy 1995;50:405-13.
  • Pichler CE, Helbling A, Pichler WJ. Three years of spe- cific immunotherapy with house-dust-mite extracts in patients with rhinitis and asthma: significant improve- ment of allergen-specific parameters and of nonspecif- ic bronchial hyperreactivity. Allergy 2001;56:301-6.
  • Durham SR. New insights into the mechanisms of immunotherapy. Eur Arch Otorhinolaryngol 1995;252 Suppl 1:S64-7.
  • Klimek L, Wolf H, Mewes T, Dormann D, Reske-Kunz A, Schnitker J, et al. The effect of short-term immunotherapy with molecular standardized grass and rye allergens on eosinophil cationic protein and tryptase in nasal secretions. J Allergy Clin Immunol 1999;103(1 Pt 1):47-53.
  • Ohashi Y, Nakai Y, Kakinoki Y, Ohno Y, Sakamoto H, Kato A, et al. Effect of immunotherapy on serum lev- els of eosinophil cationic protein in perennial allergic rhinitis. Ann Otol Rhinol Laryngol 1997;106(10 Pt 1):848-53.
There are 22 citations in total.

Details

Primary Language Turkish
Journal Section Research Article
Authors

Rauf Tahamiler This is me

Murat Yener This is me

Salih Çanakçıoğlu This is me

Publication Date August 27, 2006
Published in Issue Year 2006 Volume: 16 Issue: 4

Cite

APA Tahamiler, R., Yener, M., & Çanakçıoğlu, S. (2006). Alerjik rinitli hastalarda serum ve nazal eozinofilik katyonik proteinin immünoterapi etkinliğinin değerlendirilmesindeki rolü. The Turkish Journal of Ear Nose and Throat, 16(4), 155-159.
AMA Tahamiler R, Yener M, Çanakçıoğlu S. Alerjik rinitli hastalarda serum ve nazal eozinofilik katyonik proteinin immünoterapi etkinliğinin değerlendirilmesindeki rolü. Tr-ENT. August 2006;16(4):155-159.
Chicago Tahamiler, Rauf, Murat Yener, and Salih Çanakçıoğlu. “Alerjik Rinitli Hastalarda Serum Ve Nazal Eozinofilik Katyonik Proteinin immünoterapi etkinliğinin değerlendirilmesindeki Rolü”. The Turkish Journal of Ear Nose and Throat 16, no. 4 (August 2006): 155-59.
EndNote Tahamiler R, Yener M, Çanakçıoğlu S (August 1, 2006) Alerjik rinitli hastalarda serum ve nazal eozinofilik katyonik proteinin immünoterapi etkinliğinin değerlendirilmesindeki rolü. The Turkish Journal of Ear Nose and Throat 16 4 155–159.
IEEE R. Tahamiler, M. Yener, and S. Çanakçıoğlu, “Alerjik rinitli hastalarda serum ve nazal eozinofilik katyonik proteinin immünoterapi etkinliğinin değerlendirilmesindeki rolü”, Tr-ENT, vol. 16, no. 4, pp. 155–159, 2006.
ISNAD Tahamiler, Rauf et al. “Alerjik Rinitli Hastalarda Serum Ve Nazal Eozinofilik Katyonik Proteinin immünoterapi etkinliğinin değerlendirilmesindeki Rolü”. The Turkish Journal of Ear Nose and Throat 16/4 (August 2006), 155-159.
JAMA Tahamiler R, Yener M, Çanakçıoğlu S. Alerjik rinitli hastalarda serum ve nazal eozinofilik katyonik proteinin immünoterapi etkinliğinin değerlendirilmesindeki rolü. Tr-ENT. 2006;16:155–159.
MLA Tahamiler, Rauf et al. “Alerjik Rinitli Hastalarda Serum Ve Nazal Eozinofilik Katyonik Proteinin immünoterapi etkinliğinin değerlendirilmesindeki Rolü”. The Turkish Journal of Ear Nose and Throat, vol. 16, no. 4, 2006, pp. 155-9.
Vancouver Tahamiler R, Yener M, Çanakçıoğlu S. Alerjik rinitli hastalarda serum ve nazal eozinofilik katyonik proteinin immünoterapi etkinliğinin değerlendirilmesindeki rolü. Tr-ENT. 2006;16(4):155-9.